Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: A double-blind placebo-controlled randomised trial

Lancet

Volumn 361, Issue 9354, 2003, Pages 275-280

  Ellis, Michael ^a,b   Zwaan, Ferdinand ^b   Hedström, Ulla ^a,c   Poynton, Christopher ^d   Kristensen, Jörgen ^b   Jumaa, Pauline ^b   Wassell, Julie ^d   Al Ramadi, Basel ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b TAWAM HOSPITAL   (United Arab Emirates)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GENTAMICIN; GENTAMICIN PLUS VANCOMYCIN; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD CULTURE; CANCER CHEMOTHERAPY; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GASTROINTESTINAL MUCOSA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; IMMUNOMODULATION; MALE; MORTALITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPECIES DIFFERENCE; THORAX PAIN; TREATMENT OUTCOME;

EID: 0037464753     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12322-7     Document Type: Article

References (19)

1. Du X.X., Doerschuk C.M., Orazi A., Williams D.A. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood. 83:1994;33-37.
2. Sonis S.T., Peterson R.L., Edwards L.J., et al. Defining mechanisms of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 36:2000;373-381.
3. Petrson R.L., Wang L., Albert L., Keith J.C. Jr, Doner A.J. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest. 78:1998;1503-1512.
4. Opal S.M., Jhung J.W., Keith J.C. Jr, Goldman S.J., Palardy J.E., Parejo N.A. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factors in experimental Gram-negative sepsis. Blood. 93:1999;3467-3472.
5. Hughes W., Armstrong D., Bodey G., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. CID. 34:2002;730-751.
6. Fegan C., Poynton C., Whittaker J. The gut mucosa in bone marrow transplantation. Bone Marrow Transplant. 5:1990;373-377.
7. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
8. Cox C. Regression models and life-tables. J R Stat Soc. 34:1972;187-220.
9. Baumann H., Schendel P. Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6. J Biol Chem. 266:1991;20424-20427.
10. Gordon M.S., Mckaskill-Stevens W.J., Battiato L.A., et al. A phase I trial of recombinant interleukin-11 [Neumega rhIL-11 growth factor] in women with breast cancer receiving chemotherapy. Blood. 87:1996;3615-3624.
11. Mold C., Nakayama S., Holzer T.J., et al. C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med. 154:1981;1703-1708.
12. Weiser J.N., Pan N., McGowan K.L., et al. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing by C-reactive protein. J Exp Med. 187:1998;631-640.
13. Szalai A.J., VanCott J.L., McGhee J.R., et al. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun. 68:2000;5652-5656.
14. Trepicchio W.L., Bozza M., Pedneault G., Dorner A.J. Recombinant IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol. 157:1996;1705-1710.
15. Curti A., Ratta M., Corinti S., et al. Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood. 97:2001;2758-2763.
16. Mahboubi K., Biedermann B.C., Carroll J.M., Pober J.S. IL-11 activates human endothelial cells to resist immune-mediated injury. J Immunol. 164:2000;3837-3846.
17. Culley F.J., Thomson M., Raynes J.G. C-reactive protein increases C3 deposition on Leishmania donovani promastigotes in human serum. Biochem Soc Trans. 25:(suppl):1997;286S.
18. Opal S.M., Keith J.C., Palardy J.E., Parejo N. Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection. J Infect Dis. 181:2000;754-756.
19. Antin J.H., Lee S.J., Neuberg D., et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 29:2002;373-377.